IKT MEXC RealStocks
Own real IKT shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-18 08:46:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Inhibikase Therapeutics, Inc. (IKT) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1.39, with a market capitalization of $203.39M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.37 to $2.61. This page covers its latest market performance, valuation, price trends and company information.
$203.39M | |
$1.45 | |
$1.54 | |
$1.38 | |
$1.45 | |
578.78K | |
575.01K | |
-- | |
$2.61 | |
$1.37 | |
-- | |
-- |
Inhibikase Therapeutics, Inc. (IKT) last closed at $1.39 as of 2026-11-18 00:31:00, down 4.83% ($0.07) from the previous close of $1.45.
During the latest regular trading session, IKT traded between $1.38 and $1.54, with a volume of 578.78K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Inhibikase Therapeutics, Inc. (IKT) moved from $1.68 to $1.39, representing a decline of 17.56% ($0.29).
The stock traded between $1.37 and $1.73 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 523.34 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 1.2%
IKT is currently trading at $1.39, placing it 1.2% of the way from its 52-week low of $1.37 to its 52-week high of $2.61. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 35 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Inhibikase Therapeutics, Inc. (IKT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to IKT, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between IKT shares and USD.
IKT Shares to USD
1.00 IKT shares = 1.385 USD
Calculations are estimates based on the latest available price and are for reference only.